6:55 PM
 | 
Oct 23, 2007
 |  BC Extra  |  Company News

Speedel focuses pipeline

Speedel (SWX:SPPN) said it will focus its pipeline on avosentan (SPP301) for diabetic nephropathy and its next-generation renin inhibitors and will no longer develop pegmusirudin ( SPP200) on its own.

The company will begin a dose-finding Phase IIb trial of avosentan in 2008, with...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >